BMEZ News and Press, BlackRock Health Sciences Trust II of Beneficial Interest From 04/20/23

2023-04-20 12:12:30 ET Summary BMEZ launched right before Covid, riding up the boost when speculative growth took off. In 2022, the story was much different, and the fund struggled significantly. This fund is much riskier than its older sister fund, BME, but it also can provid...

2023-04-19 15:53:10 ET Summary Invesco CEF Income Composite ETF is a fund of closed-end funds. PCEF has outperformed its competitor Amplify High Income ETF in the last 10 years. However, historical return, distribution growth and holding discount are concerning. Bonus: A s...

Please replace the release dated April 11, 2023, with the following corrected version due to changes in the table, "Summary of share repurchase activity since Repurchase Program inception as of March 31, 2023" . The updated release reads: BLACKROCK CLOSED-END FUND SHARE REPURCHASE P...

BlackRock Advisors, LLC (“BlackRock”) announced today name changes for five BlackRock closed-end funds with contingent limited terms (each, a “Trust”). The name changes are being made to increase awareness of the contingent limited term structure and the fact that ther...

Bull or bear? Who cares when we can collect dividends between 10.1% and 11.8% . That’s not a typo. The S&P 500 pays 1.7%. The 10-year Treasury yields two points more at 3.7%. That’s better—but it ain’t 11.8%! The same million-dollar retirement portf...

BlackRock today announced the release of quarterly fund commentaries for BlackRock Innovation and Growth Trust (NYSE: BIGZ), BlackRock Science and Technology Trust II (NYSE: BSTZ), BlackRock Health Sciences Trust II (NYSE: BMEZ), BlackRock Capital Allocation Trust (NYSE: BCAT), BlackRock ESG Capi...

Summary BME is a large-cap focused health care CEF. It pays a generous 5.9% distribution yield. Although they share similar names and structure, BME and BMEZ are managed in fundamentally different ways. Investors need to be careful not to get them mixed up. Recently, I wro...

Summary BMEZ’s portfolio has a combination of unknown small-cap "next generation" healthcare holdings and some familiar names in the field of biotechnology. Lack of diversification makes BMEZ susceptible to sector-specific risk. It also has a relatively high expense ratio despite...

Summary The BMEZ fund combines investments in 'next generation' healthcare stocks with pre-IPO private investments. The fund also pays a high current distribution funded through option writing and returns of capital. With poor risk sentiment, the IPO market appears to be frozen. I w...

Good news: this dreadful year has created the conditions for a nice market bounce in 2023. And we CEF investors are in a nice position to capitalize with 9.8% dividends and potential 38%+ total returns next year. I’ll name three closed-end funds (CEFs) with discounts big enough to deli...